Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decapeptyl for OHSS Prevention in IVF
NCT01714648Phase 4Terminated
- Sponsor
- Elisha Hospital
- Start
- Nov 2012
- Primary completion
- Jan 2014
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of triptorelin in ovarian hyperstimulation syndrome (OHSS), sponsored by Elisha Hospital. Primary endpoint: Number of Participants with Adverse Events as a Measure of Safety: The adverse event is the development of OHSS at 12 days. Started Nov 2012; status: terminated.
02
Drugs
triptorelin
03
Conditions
ovarian hyperstimulation syndrome (OHSS)
Beyond the preview
Go deeper on NCT01714648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01714648.